The 2020 COVID-19 pandemic undermines the world economy, the affordability and accessibility of our health systems. It puts an increasing strain on global production, supply and value chains. The research and development of a set of COVID-19 vaccines is an unprecedented triumph of rapid innovation. The sense of urgency has prompted academic research institutions, big pharmaceuticals and dedicated biotechnology companies to develop vaccines targeting the SARS-CoV-2 coronavirus disease. Simultaneously, it unlocks new value for business, patients and society. Consequently, new business models have come to the forefront.